On October 13, 2025, Eli Lilly and Company announced it will present new clinical data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Annual Meeting, scheduled for October 17-21 in Berlin. A key highlight will be the late-breaking oral presentation of the primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in patients with HR+, HER2-, node-positive, high-risk early breast cancer. The presentation of overall survival data is a critical milestone for any cancer drug and has the potential to significantly impact its use and market position. In addition to the Verzenio data, Lilly will also present findings for several investigational therapies targeting various cancers, showcasing the breadth of its oncology pipeline. This announcement is significant as positive long-term data for Verzenio, a key drug for the company, could reinforce its blockbuster status. No specific market reaction on October 14, 2025, has been detailed in the available information.